Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis
Conclusions:
Benralizumab reduced the risk of SAEs, asthma exacerbation, bronchitis and sinusitis, and aggravated the risk of headache and pyrexia. Other AEs were comparable between the benralizumab group and placebo group. Therefore, benralizumab is a relatively safe drug, but vigilance regarding AEs is imperative during long-term treatment.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research
More News: Asthma | Back Pain | Bronchitis | Common Cold | Cough | Databases & Libraries | Headache | Influenza | Internal Medicine | Migraine | Pain | Respiratory Medicine | Sinusitis | Study